<DOC>
	<DOCNO>NCT01216670</DOCNO>
	<brief_summary>The CARRYING ON heart failure ( HF ) study national , prospective , post market interventional , multi-center , open-label , pilot trial.The purpose study assess short term long term period , incidence pre-specified clinical arrhythmic event patient low ejection fraction ( EF ) hospitalize acute cardiac decompensation .</brief_summary>
	<brief_title>Cardiac Rhythm Monitoring After Acute Decompensation Heart Failure</brief_title>
	<detailed_description>The CARRYING ON heart failure ( HF ) study national , prospective , post market interventional , multi-center , open-label , pilot trial design two phase . The purpose study assess short term ( 6 month follow-up - Phase 1 ) long term period ( 24 month follow-up - Phase 2 ) , incidence pre-specified clinical arrhythmic event patient low ejection fraction ( EF ) hospitalize acute cardiac decompensation . A previously implant Reveal® XT device use collect heart rhythm information .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject history least one heart failure ( HF ) hospitalization ( defined European Society Cardiology American College Cardiology/American Heart Association guideline ) , emergency department ( ED ) visit , urgent office visit necessitate intravenous ( IV ) diuretic augmentation oral diuretic , IV inotropic , IV vasodilator HF parenteral therapy within 15 day prior device implant Subject implant Reveal® XT device ( le 15 day post implant ) ; Ejection Fraction ( EF ) less 40 percent Patient access telephone line Patient patient 's caregiver willing able use Medtronic CareLink® Network Monitor perform require duty home family member assistant perform duty Age great 18 year old Patient willing able comply Clinical Investigation plan willing remain available followup visit , study closure Patient ( patient 's legally authorize representative ) willing able sign date study Informed Consent New York Heart Association ( NYHA ) Class IV ( chronic ambulatory ) Planned previous implant implantable cardioverterdefibrillator pacemaker device Patient 's life expectancy le one year due non cardiovascular disorder , opinion physician Severe chronic obstructive pulmonary disorder ( COPD ) Chronic Atrial Fibrillation time enrollment ST segment elevation time electrocardiogram Cognitive disease Pregnancy childbearing potential reliable contraceptive Anticipated compliance problem participation another competitive trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Reveal® XT</keyword>
	<keyword>Acute Heart Failure</keyword>
	<keyword>Low Ejection Fraction</keyword>
	<keyword>Reveal® XT implant</keyword>
</DOC>